Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for operating expenses in the first three quarters of 2025, with expectations of significant revenue in the fourth quarter to offset these expenses [30][31] - The company anticipates a good fourth quarter, which will help cover operating expenses through the number of financings being conducted [31][32] - The market value of the company's equity holdings in Pollex Bio and Buddha Juice is expected to provide substantial upside for shareholders [31][32] Business Line Data and Key Metrics Changes - The company aims to scale its operations to launch three to five companies per year, moving from a historical average of one launch every 18 months [9][23] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than historical ones [23][24] Market Data and Key Metrics Changes - The microcap market has been challenging, but there is optimism that transparency and liquidity in public markets will become attractive again [28][29] - The company is seeing a resurgence in demand for small public companies, as many are moving away from private equity and venture capital routes [29][51] Company Strategy and Development Direction - The company is focused on building a unique public venture platform that supports the launch of public companies, emphasizing the importance of operational bandwidth and community involvement [9][15] - The strategy includes curating high-potential companies and transforming them into investable public entities, with a focus on both deep tech and consumer products like Buddha Juice [12][58] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current market challenges but remains optimistic about the future of public venture, believing that the company is well-positioned to capitalize on upcoming opportunities [28][39] - The management is committed to improving communication with shareholders and addressing concerns about the company's stock performance [68][70] Other Important Information - The company is exploring the potential of a spinout involving PatentVest, which is expected to disrupt the patent law sector significantly [34][63] - The company is also working on enhancing its investor relations efforts to better communicate its value proposition and portfolio performance [68][70] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The management's philosophy is to distribute dividends when the company has a developed market and broader ownership, avoiding any hindrance to company development [41] Question: How will MDB handle dilution during fundraising for Exazyme? - Shareholders can expect dilution as companies raise more capital, but efforts will be made to minimize this dilution [42] Question: What is MDB's role regarding Heartbeat and its FDA approval? - The management emphasizes the importance of FDA approval for Heartbeat, which will facilitate future fundraising efforts [45] Question: Why is the stock trading at a low price compared to its IPO? - The management attributes the low stock price to a poor microcap market, concerns about the company's ability to select successful ventures, and year-end tax selling [46][47] Question: What makes the cost of being public more favorable for listings? - The management believes that profitable microcap companies are trading at attractive valuations, making it sensible for them to go public [49][51] Question: How does MDB differentiate between deep tech and consumer products like Buddha Juice? - The management clarifies that both categories are viable, with a focus on launching category leaders that have a competitive edge [57][58]
MDB Capital (MDBH) - 2025 Q3 - Earnings Call Transcript